Background The efficacy of programmed death-1 blockade in epidermal growth factor
receptor gene (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) patients with …

Purpose: Although the efficacy of programmed cell death–1 (PD-1) blockade is generally
poor for non–small cell lung cancer (NSCLC) with activating mutations of the epidermal …

Purpose: The impact of EGFR tyrosine kinase inhibitors (TKI) on the tumor immune
microenvironment (TME) in non–small cell lung cancer (NSCLC) is unclear. Experimental …

Introduction Besides being a predictive biomarker of response to immunotherapy in lung
cancer in general, programmed death-ligand 1 (PD-L1) is not so well correlated with …

Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) has
significantly improved clinical outcomes compared with chemotherapy in non-small cell lung …

Background Treatment with epidermal growth factor receptor (EGFR)‐tyrosine kinase
inhibitors (TKIs) leads to initial response in most patients with EGFR‐mutated non‐small cell …

PURPOSE The phase III CheckMate 722 trial (ClinicalTrials. gov identifier: NCT02864251)
evaluated nivolumab plus chemotherapy versus chemotherapy in patients with epidermal …

Introduction This study evaluated whether tumor expression of programmed death ligand 1
(PD-L1) could predict the response of EGFR-mutated NSCLC to EGFR tyrosine kinase …

8022 Background: Erlotinib is FDA-approved for the first-line treatment of EGFR MT NSCLC,
with a median progression free survival (PFS) of 10.4 months. Nivolumab, a fully human …

Patients with EGFR mutations showed unfavorable response to programmed cell death-1
(PD-1) blockade immunotherapy in non-small cell lung cancer (NSCLC). Yet the underlying …